Form 4: SOPHiA GENETICS Insider Sells Shares for Tax Obligations

SOPHiA GENETICS SA reports that Chief Sales Officer Kevin Puylaert sold shares to cover tax obligations related to vested restricted stock units.

Summary

• Kevin Puylaert, Chief Sales Officer of SOPHiA GENETICS SA, reported the sale of 548 ordinary shares on April 6, 2026, at a price of $4.86 per share.
• An additional 46 ordinary shares were sold on the same date at $4.86 per share.
• Furthermore, 30 ordinary shares were sold on April 6, 2026, at $4.83 per share.
• These sales were conducted to satisfy tax obligations arising from the vesting of restricted stock units on April 2 and April 3, 2026.
• The transactions were executed as 'sell to cover' and are not considered discretionary trades.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the insider sales are directly tied to tax obligations from vested equity awards and are not indicative of a negative view on the company's prospects.

Negatives

• Insider selling occurred, although it was for tax obligations related to vested RSUs.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock activity. The 'sell to cover' nature of these sales is a common practice to manage tax liabilities upon vesting of equity awards.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even for tax purposes, can sometimes be perceived negatively, though the 'sell to cover' nature mitigates this concern.
• Employees: The filing relates to equity awards, which are a form of employee compensation.
• Management: The filing details transactions by a key executive, the Chief Sales Officer.

Key Dates

Keywords

SOPHiA GENETICS SA, SOPH, Form 4, Insider Trading, Stock Sale, Tax Obligations, Restricted Stock Units, Securities Exchange Act